Welcome to our dedicated page for HEARTFLOW news (Ticker: HTFL), a resource for investors and traders seeking the latest updates and insights on HEARTFLOW stock.
Heartflow, Inc. (Nasdaq: HTFL) is a medical technology company that uses artificial intelligence and coronary computed tomography angiography (CTA) to deliver non-invasive coronary artery disease (CAD) detection and management solutions. This news page aggregates company press releases and third-party coverage related to Heartflow’s technology, clinical research, reimbursement milestones, and corporate developments.
Readers can find updates on Heartflow’s Heartflow One platform, including FFRCT Analysis, Plaque Analysis, and PCI Navigator, as the company reports new clinical data, registry results, and real-world evidence. News items often highlight findings from large studies such as FISH&CHIPS and the DECIDE registry, which Heartflow cites to demonstrate prognostic value, changes in medical management, and potential cost savings associated with its AI-driven coronary assessments.
The feed also features announcements about payer coverage and coding, including coverage decisions by major U.S. insurers and information on Category I CPT coding for Heartflow Plaque Analysis. These updates provide context on how access to Heartflow’s non-invasive plaque quantification and coronary physiology tools is evolving within healthcare systems.
In addition, visitors can review Heartflow’s participation in major cardiology and healthcare conferences, such as scientific sessions hosted by the American Heart Association, the European Association of Cardiovascular Imaging, and large investor and industry meetings. These items typically summarize late-breaking data presentations, new product introductions, and company commentary on the role of AI in precision cardiovascular care. Investors, clinicians, and other stakeholders can use this page as a centralized source for ongoing developments related to HTFL and its CAD-focused health information services.
Heartflow (Nasdaq: HTFL) announced new clinical evidence and launched the NAVIGATE-PCI registry to advance AI-guided CAD care. Key findings include a cohort of >15,000 patients with up to 16 years follow-up showing extensive plaque volume confers a 4x higher MACE risk, DECIDE data on ~3,800 patients improving lipid outcomes, and a US payer budget analysis projecting $140 million population savings and cost-effectiveness within two years. The NAVIGATE-PCI Registry has enrolled its first patient toward a planned 5,000-patient evaluation of CT-guided PCI planning.
Heartflow (Nasdaq: HTFL) announced management will participate in a fireside chat at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco on March 3, 2026.
The presentation is scheduled for 10:45 a.m. PT / 1:45 p.m. ET, with a live webcast and archived replay available via the company's Investor Relations website.
Heartflow (Nasdaq: HTFL) will report fourth quarter and full year 2025 financial results after market close on March 18, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day with a live webcast and archived replay available for 12 months.
Investors must register to receive dial-in numbers and a unique PIN; participants are encouraged to register at least 15 minutes before the call.
Heartflow (Nasdaq: HTFL) announced expansion of its GAMEFILM Registry on February 12, 2026 to include former NBA and NHL players, building on an initial phase with NFL alumni.
The non-invasive registry uses AI-powered Heartflow Plaque Analysis with CCTA across 15 U.S. sites, has enrolled over 140 retired athletes and aims for up to 300 participants to study coronary plaque and risk.
Heartflow (Nasdaq: HTFL) announced that Aetna now covers Heartflow Plaque Analysis across Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans, effective December 23, 2025 for patients with acute or stable chest pain and 1–69% coronary stenosis on coronary CTA. This makes Aetna the fourth major national payer to align coverage with EviCore and expands access to the majority of insured lives in the U.S.
Reimbursement moved forward with new Category I CPT code 75577 effective January 1, 2026, establishing 0.85 RVUs for physicians and a combined total of 4.00 RVUs. The release cites real-world evidence including the DECIDE Registry (>50% management change) and FDA clearance with 95% agreement to IVUS.
Heartflow (Nasdaq: HTFL) said company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast and archived replay will be available on Heartflow's Investor Relations website at https://ir.heartflow.com.
The presentation will cover recent company developments and outlook for investors; timing and access details are provided for shareholders and analysts.
Heartflow (Nasdaq: HTFL) announced that the American College of Cardiology and American Heart Association published scientific statements endorsing the prognostic value of quantitative coronary plaque assessment and highlighting the coronary CTA + Heartflow pathway for personalized CAD management on Dec 18, 2025.
Heartflow said its Plaque Analysis is the only FDA-cleared, AI-powered plaque quantification tool with 95% agreement to IVUS using blinded core-lab adjudication. The company cited real-world evidence including the DECIDE registry, where Plaque Analysis changed medical management in more than 50% of patients, and a FISH&CHIPS cohort validation presented at AHA 2025.
Heartflow (Nasdaq: HTFL) announced two large real-world analyses from FISH&CHIPS (England NHS) covering >90,000 patients, presented at EACVI on Dec 11, 2025. The reports show lesion-specific FFRCT predicts individual outcomes: patients with the lowest FFRCT had a 4× higher MI risk and 3× higher cardiovascular death risk, independent of traditional risk factors. A separate health‑economic analysis found £1,042 GBP ($1,394 USD) per‑patient savings at two years, with modeled system savings of about £25 million GBP ($33.45 million USD) per year and reduced downstream testing and increased appropriate revascularization.
Findings support clinical and economic value of the Heartflow One platform and lesion-specific FFRCT in large health systems.
Heartflow (Nasdaq: HTFL) said management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:30 p.m. PT / 3:30 p.m. ET. The session will be available live and archived on the company's Investor Relations website.
Investors can access the webcast and archived replay at https://ir.heartflow.com.
Heartflow (Nasdaq: HTFL) reported third quarter 2025 results on November 12, 2025, with total revenue of $46.3 million, up 41% YoY, and gross margin of 76.5%. The company posted a net loss of $50.9 million (loss per share $1.04), which included a $32.1 million noncash warrant remeasurement charge and a $6.4 million loss on extinguishment of debt. Heartflow completed an IPO in August 2025, raising approximately $364.2 million, and had $291.2 million in cash and equivalents as of September 30, 2025.
The company initiated full-year 2025 revenue guidance of $173.0 million to $173.5 million (≈37.5%–38.0% growth). Operational highlights include broad commercial payor coverage for Heartflow Plaque Analysis and DECIDE registry findings showing medical management change in over half of patients versus CCTA alone.